VIE

Viela Bio

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$385.2M

Burn Rate (Qtr)

$37.6M

Company Profile

At Viela Bio, our mission is to improve the lives of those impacted by serious, underserved inflammatory and autoimmune diseases. We lead with scientific innovation and are firm believers in cultivating an environment that fosters creativity and collaboration.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Uplizna® (inebilizumab-cdon)

Neuromyelitis Optica Spectrum Disorder

Quarterly Sales (Approved)

March 26, 2021 (Est)

Inebilizumab-cdon (Anti-CD19 mAb)

Myasthenia Gravis

Phase 3 (Data)

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon